NEO212, temozolomide conjugated to NEO100, exerts superior therapeutic activity over temozolomide in preclinical chemoradiation models of glioblastoma.

Radu O MineaThu Zan TheinZhuoyue YangMihaela CampanPamela M WardAxel H Schönthal Thomas C Chen

Published in: Neuro-oncology advances (2024)

NEO212 is a candidate drug to potentially replace TMZ within the standard Stupp protocol. It has the potential to become the first chemotherapeutic agent to significantly extend overall survival in TMZ-resistant patients when combined with radiation.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
randomized controlled trial
peritoneal dialysis
rectal cancer
emergency department
squamous cell carcinoma
bone marrow
cell therapy
radiation therapy
electronic health record